Trial Profile
Clinical Trials Insight: 700020717
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2008
Price :
$35
*
At a glance
- Drugs INGN 225 (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Introgen Therapeutics
- 14 Feb 2008 Results reported at ASCO 2007.
- 06 Feb 2007 New trial record.